ow molecular weight heparin in advanced non small cell lung cancer (NSCLC): a randomized open label phase III study evaluating the effect of enoxaparin (Clexane) on survival and symptom control in patients with stage IIIb and IV NSCLC undergoing a cisplatin based first line chemotherapy: the syringes trial - SYRINGES

TOGA Thoracic Oncology Group Antwerp0 个研究点开始时间: 2008年3月12日最近更新: 2017年8月21日

试验速览

暂无简介。

•-Locally advanced or metastatic NSCLC (stage IIIB-IV) -patients who are not candidates for radical combined modality treatments or high-dose radiation therapy
•-At least one measurable lesion according to RECIST criteria
•-Good performance status (KPS 100-70)
•-Age =18 years.
•-Adequate haematological, renal and liver function
•-Written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•-Previous chemotherapy for NSCLC
•-Brain metastasis
•-history of cerebral haemorrhage, neurosurgery within 3 previous months or Surgery within the past 6 weeks
•-Indication for anticoagulant therapy or thrombolytic therapy
•-Concomitant therapy with an anti-angiogenesis agent
•-Contra-indication for LMWH
•-Life expectancy of <3 months.
•-Serious concomitant systemic disease, uncontrolled arterial hypertension, Active peptic ulcer or other condition which do not permit study treatment or follow up required to comply with the study protocol

发起方

TOGA Thoracic Oncology Group Antwerp